Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Novartis Signs Deals In Migraine & Diabetes

Executive Summary

Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.

Advertisement

Related Content

Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance
Topas Bags Big Pharma Partner With Lilly Pact
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market
Ferring Looks For Early Microbiome Wins, But Willing To Do Heavy Lifting
Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab
Immune-Focused Discovery Firm Alpine Goes Public With Nivalis Merger
Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098607

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel